Dysregulation of the transforming growth factor-Î²1 (TGF-Î²1)/selected small mother against decapentaplegic (SMAD) pathway can be implicated in development of age-related macular degeneration (AMD), and the delivery of TGF-Î²1 could be beneficial for AMD. We developed a new ophthalmic formulation of TGF-Î²1 assessing the ocular pharmacokinetic profile of TGF-Î²1 in the rabbit eye. Small unilamellar vesicles (SUV) loaded with TGF-Î²1 were complemented with Annexin V and Ca2+, and the vitreous bioavailability of TGF-Î²1 was assessed after topical ocular administration by a commercial ELISA kit. We detected high levels of TGF-Î²1 (Cmax114.7 Â± 12.40 pg/mL) in the vitreous after 60 min (Tmax) from the topical application of the liposomal suspension. Ocular tolerability was also assessed by a modified Draizeâs test. The new formulation was well tolerated. In conclusion, we demonstrated that the novel formulation was able to deliver remarkable levels of TGF-Î²1 into the back of the eye after topical administration. Indeed, this TGF-Î²1 delivery system may be useful in clinical practice to manage ophthalmic conditions such as age-related macular degeneration, skipping invasive intraocular injections.
|Titolo:||Topical ocular delivery of TGF-β1 to the back of the eye: Implications in age-related neurodegenerative diseases|
|Data di pubblicazione:||2017|
|Appare nelle tipologie:||1.1 Articolo in rivista|